Market Cap 3.59B
Revenue (ttm) 62.38M
Net Income (ttm) -101.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -162.86%
Debt to Equity Ratio 0.00
Volume 6,857,900
Avg Vol 3,263,140
Day's Range N/A - N/A
Shares Out 144.24M
Stochastic %K 19%
Beta 1.22
Analysts Strong Sell
Price Target $23.90

Company Profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repress...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 320 4900
Address:
201 Brookline Avenue, Suite 901, Boston, United States
Jonita
Jonita May. 15 at 5:33 PM
$TNGX in in in
0 · Reply
StocktwitsNews
StocktwitsNews May. 15 at 5:20 PM
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside $TNGX $IWM $XBI https://stocktwits.com/news/equity/markets/tngx-stock-worst-day-19-months-after-0-revenue-q1-price-target-double/cZXmP6LRek5
0 · Reply
justiceforb_85
justiceforb_85 May. 15 at 4:59 PM
$TNGX added. Look forward to vopimetostat data in combination with $RVMD.
0 · Reply
benwcan
benwcan May. 15 at 4:51 PM
$TNGX looking for that bottom…
0 · Reply
Quantumup
Quantumup May. 14 at 8:27 PM
Mizuho⬆️ $TNGX's PT to $30 and⬆️1L PDAC PoS to 75% while reiterating at an Outperform rating and saying: TNGX reported 1Q26 EPS and provided a pipeline update. $RVMD $IMRX ERAS BBOT Mizuho added—While all previously guided 2026 clinical updates (vopi-RAS(ON) combos, vopi in NSCLC and TNG456 in GBM) remain on track, TNGX noting that the registrational strategy for vopimetostat is under review (previously expected to start Phase III 2L PDAC trial). This decision was driven in part by the emerging RAS(ON) combo data, increased conviction in a path to 1L PDAC and a determination that capital allocation to this opportunity would be most impactful. We continue to believe vopi+RAS(ON) are positioned to demonstrate clinically meaningful additive benefit and are taking up our 1L PDAC POS (50%-->75%) on the basis of full RAS(ON) validation (via daraxonraib's RASolute 302). Reiterate Outperform with PT to $30 from $20, driven entirely by increased 1L PDAC risk-adjusted revenue assumptions.
1 · Reply
biolover
biolover May. 14 at 7:34 PM
$ERAS $RVMD $TNGX Does this group understand what they post 😂
2 · Reply
biolover
biolover May. 14 at 7:30 PM
$VKTX Look how $TNGX management Jumps to rescues story when there are non sense rumors. VS BL selfish , scared and conservative statements.
2 · Reply
StockMomentumLab
StockMomentumLab May. 13 at 9:20 PM
$TNGX What used to be front-and-center (the 2L pancreatic Phase 3 focus) is now de-emphasized, with messaging pivoting toward combo strategies — especially pairing with $RVMD and potentially future combinations like $ERAS in H2 2026. They’re also widening the story into multiple shots on goal: lung cancer data, GBM, and broader combo potential around vopimetostat with RAS(ON) inhibition. That quote basically tells you the direction of travel: less single-indication conviction, more platform-style combination framing. Market will usually reward that only if early combo data actually de-risks efficacy. Otherwise, it reads as pipeline stretching to keep optionality alive. Tape will care about data, not strategy language. 👉Click to view @StockMomentumLab for timely updates amid the volatility.
1 · Reply
focafoca99
focafoca99 May. 13 at 8:17 PM
$TNGX reports Q1 2026 results with $380M cash, board resignations and pipeline progress updates.
0 · Reply
AbovetheGreenLine
AbovetheGreenLine May. 13 at 4:29 PM
$TNGX is Don't Take a Loss! https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/M2fzPjiJH95X
0 · Reply
Latest News on TNGX
Tango Therapeutics falls -19.7%

2026-05-15T17:52:59.000Z - 11 hours ago

Tango Therapeutics falls -19.7%


Tango Therapeutics falls -14.9%

2026-05-15T14:19:01.000Z - 15 hours ago

Tango Therapeutics falls -14.9%


Tango Therapeutics reports Q1 EPS (32c), consensus (31c)

2026-05-13T20:44:37.000Z - 2 days ago

Tango Therapeutics reports Q1 EPS (32c), consensus (31c)


Tango Therapeutics sees cash runway into 2028

2026-05-13T20:42:23.000Z - 2 days ago

Tango Therapeutics sees cash runway into 2028


Tango Therapeutics initiated with a Buy at Canaccord

2026-04-02T09:15:09.000Z - 6 weeks ago

Tango Therapeutics initiated with a Buy at Canaccord


Tango Therapeutics Appoints Sung Lee to Board of Directors

Jan 5, 2026, 7:00 AM EST - 4 months ago

Tango Therapeutics Appoints Sung Lee to Board of Directors


Tango Therapeutics Transcript: Study Update

Oct 23, 2025, 8:30 AM EDT - 7 months ago

Tango Therapeutics Transcript: Study Update


Tango Therapeutics Announces $225 Million Financing

Oct 23, 2025, 7:20 AM EDT - 7 months ago

Tango Therapeutics Announces $225 Million Financing


Tango Therapeutics to stop development of cancer therapy

May 23, 2024, 7:19 AM EDT - 2 years ago

Tango Therapeutics to stop development of cancer therapy


Tango Therapeutics Announces Discontinuation of TNG348 Program

May 23, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces Discontinuation of TNG348 Program


Tango Therapeutics Announces Updates to Its Board of Directors

Aug 29, 2023, 5:08 PM EDT - 2 years ago

Tango Therapeutics Announces Updates to Its Board of Directors


Jonita
Jonita May. 15 at 5:33 PM
$TNGX in in in
0 · Reply
StocktwitsNews
StocktwitsNews May. 15 at 5:20 PM
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside $TNGX $IWM $XBI https://stocktwits.com/news/equity/markets/tngx-stock-worst-day-19-months-after-0-revenue-q1-price-target-double/cZXmP6LRek5
0 · Reply
justiceforb_85
justiceforb_85 May. 15 at 4:59 PM
$TNGX added. Look forward to vopimetostat data in combination with $RVMD.
0 · Reply
benwcan
benwcan May. 15 at 4:51 PM
$TNGX looking for that bottom…
0 · Reply
Quantumup
Quantumup May. 14 at 8:27 PM
Mizuho⬆️ $TNGX's PT to $30 and⬆️1L PDAC PoS to 75% while reiterating at an Outperform rating and saying: TNGX reported 1Q26 EPS and provided a pipeline update. $RVMD $IMRX ERAS BBOT Mizuho added—While all previously guided 2026 clinical updates (vopi-RAS(ON) combos, vopi in NSCLC and TNG456 in GBM) remain on track, TNGX noting that the registrational strategy for vopimetostat is under review (previously expected to start Phase III 2L PDAC trial). This decision was driven in part by the emerging RAS(ON) combo data, increased conviction in a path to 1L PDAC and a determination that capital allocation to this opportunity would be most impactful. We continue to believe vopi+RAS(ON) are positioned to demonstrate clinically meaningful additive benefit and are taking up our 1L PDAC POS (50%-->75%) on the basis of full RAS(ON) validation (via daraxonraib's RASolute 302). Reiterate Outperform with PT to $30 from $20, driven entirely by increased 1L PDAC risk-adjusted revenue assumptions.
1 · Reply
biolover
biolover May. 14 at 7:34 PM
$ERAS $RVMD $TNGX Does this group understand what they post 😂
2 · Reply
biolover
biolover May. 14 at 7:30 PM
$VKTX Look how $TNGX management Jumps to rescues story when there are non sense rumors. VS BL selfish , scared and conservative statements.
2 · Reply
StockMomentumLab
StockMomentumLab May. 13 at 9:20 PM
$TNGX What used to be front-and-center (the 2L pancreatic Phase 3 focus) is now de-emphasized, with messaging pivoting toward combo strategies — especially pairing with $RVMD and potentially future combinations like $ERAS in H2 2026. They’re also widening the story into multiple shots on goal: lung cancer data, GBM, and broader combo potential around vopimetostat with RAS(ON) inhibition. That quote basically tells you the direction of travel: less single-indication conviction, more platform-style combination framing. Market will usually reward that only if early combo data actually de-risks efficacy. Otherwise, it reads as pipeline stretching to keep optionality alive. Tape will care about data, not strategy language. 👉Click to view @StockMomentumLab for timely updates amid the volatility.
1 · Reply
focafoca99
focafoca99 May. 13 at 8:17 PM
$TNGX reports Q1 2026 results with $380M cash, board resignations and pipeline progress updates.
0 · Reply
AbovetheGreenLine
AbovetheGreenLine May. 13 at 4:29 PM
$TNGX is Don't Take a Loss! https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/M2fzPjiJH95X
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 11 at 2:55 PM
$TNGX RSI: 37.28, MACD: 0.6452 Vol: 1.88, MA20: 24.56, MA50: 20.85 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
biolover
biolover May. 10 at 4:59 AM
$TNGX FMR increased form 2.5 M to 10 M shares in q1. That big part of meteoric rise in q1
0 · Reply
focafoca99
focafoca99 May. 8 at 2:02 PM
$TNGX confirms CFO Daniella Beckman's departure and details a separation agreement with 12 months severance, COBRA reimbursement and
0 · Reply
AbovetheGreenLine
AbovetheGreenLine May. 5 at 7:03 PM
Swing Trade Buy on the Close for Tango Thera. $TNGX. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/NuLe3
0 · Reply
bobaboiz
bobaboiz Apr. 30 at 4:16 PM
$TNGX $ERAS mmm yummy dips
0 · Reply
bobaboiz
bobaboiz Apr. 27 at 9:47 PM
$ERAS $TNGX next?
0 · Reply
Jstockdaddy
Jstockdaddy Apr. 22 at 2:15 PM
$CAR come to $TNGX the squeeze is looking epic. Institutions own over 100% because 40 mil shares are short ! Ticking time bomb here
0 · Reply
Jhoooon
Jhoooon Apr. 22 at 11:53 AM
$BMEA @anhteo I understand any scepticism. But as long as a biopharma becomes able to prove its science, now horizons become possible, especially amif the TAM (total adressable market) is huge like with td2/obesity). Want an example? Take a look at $TNGX (Tango Therapeutics). Was a dying stock no later than May 2025 with an historical lowest at $1.03. Now, lest than a year later (april 26, today), it's around $29 and market cap around $4B (continuously going up). They've been able to prove their science and then tie proprer partnership. If/when biomea manage to do the same, new horizons will become possible, even if for now we cannot hardly imagine that (rightly so).
0 · Reply
mohamettarik
mohamettarik Apr. 21 at 10:19 PM
$TNGX it is pumped by insiders mr smart. The announced start few days back, ATM soon. If you know $TNXP you should be more aware of small biotech trading. They live as parasites on your money years after years till have something in market or got acquired.
1 · Reply
Jstockdaddy
Jstockdaddy Apr. 21 at 7:12 PM
$TNGX wen BO?
1 · Reply
Rmccall
Rmccall Apr. 21 at 7:07 PM
$TNGX just keep buying more!!
0 · Reply
TA_Kongen
TA_Kongen Apr. 20 at 6:47 PM
$CAR $FRMM $KALV $TTEC $TNGX Hopefully CAR will trigger some short squeeze sympathy across the board. Here are a few of my faves.
1 · Reply